Stoke Therapeutics Inc at Cowen Health Care Conference Transcript
(inaudible) on our orphan epilepsies corporate panel today at the 43rd annual healthcare conference. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And I am joined by my colleagues, Brendan Smith and Athena Chin. And it is our pleasure to have with us today a great corporate panel. We have CSO of Marinus Pharmaceuticals, Alex Aimetti; CEO of Ovid, Jeremy Levin; Marcio Souza, CEO of Praxis; and Edward Kaye, CEO of Stoke Therapeutics. So thank you all for joining us.
Questions & Answers
We're going to start the conversation with a few thematic questions and then dive into some company-specific round robin a little bit. So maybe just to start, when you're thinking about new indications to look at, maybe what are the most important clinical and regulatory considerations for developing drugs specifically for orphan epilepsies, and maybe, Alex, we can kick it off with you?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |